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Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder 
correlated with a decrease in brain dopamine and an increase in behavioral symptoms 
of hyperactivity and impulsivity. This experiment explored how tartrazine (Yellow 
#5) impacts these symptoms. After tartrazine administration to Spontaneously 
Hypertensive Rats (SHR), dopamine concentrations in regions of brain tissue were 
measured using Enzyme-Linked Immunosorbent Assay analysis. Behavioral testing 
with a T-maze and open field test measured impulsivity and hyperactivity, 
respectively. Results indicate that dietary tartrazine increases hyperactive behaviors in 
the SHR. However, results do not indicate a relationship between dietary tartrazine 
and brain dopamine. No conclusions regarding the relationship between dietary 
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Attention Deficit Hyperactivity Disorder (ADHD) is the most prevalent 
neurodevelopmental pediatric disorder in the United States, affecting approximately 
5% of all school-aged children (Wilens, 2003).  ADHD is characterized by symptoms 
of impulsivity, hyperactivity, and behavioral inhibition (Purdie et al., 2002).  
Furthermore, individuals with ADHD appear to have abnormal levels of the 
neurotransmitter dopamine and dopamine-related transporters and receptors (Volkow 
et al., 2009). In the last decade, there has been a sudden rise in the number of 
documented cases of ADHD.  This is partially due to the appearance of symptoms in 
varying degrees of severity and modifications in the standards used for diagnosing 
ADHD. (Purdie et al., 2002)    
The increase in the diagnoses of ADHD is attributed in part to its history of 
misdiagnosed cases.  In the past, many children who demonstrated symptoms of 
excessive impulsivity, hyperactivity, or behavioral inhibition would receive 
disciplinary action instead of an assessment to test for possible neurodevelopmental 
disorders such as ADHD (Meschan & Earls, 2005).  As parents and teachers have 
become more aware of ADHD symptoms there has been a trend to seek diagnosis and 
pre-emptive evaluation sooner.  Additionally, the number of diagnoses among boys is 
significantly higher than those among girls (Purdie et al., 2002).  This difference may 
be due to the lack of the disruptive nature of the behavioral symptoms associated with 
ADHD among girls.  In diagnosed cases of ADHD in males, these disruptive 
 2 
 
behavioral symptoms are more prevalent, causing the discrepancy in diagnoses 
(Meijer et al., 2009). 
The diagnosis process is typically very long, tedious, and inconsistent.  
Despite its high prevalence as a common disorder, ADHD has no cure, and methods 
of treatment are simply targeted at reducing or temporarily eliminating symptoms 
(Fan & Hess, 2006).  These treatments include behavioral therapy, parental 
interventions, and educational modification (Purdie et al., 2002).  However, the most 
prevalent and immediate treatment of ADHD symptoms is pharmacotherapy—the use 
of psychostimulants to reduce excess motor activity and enhance concentration (Fan 
& Hess, 2006).  The most common psychostimulants are methylphenidate (common 
name Ritalin) and amphetamine (common name Adderall; Fan & Hess, 2006).   
Though pharmacotherapy has proven to be effective in the treatment of 
ADHD, many patients experience negative side effects of these drugs, including 
severe insomnia, appetite suppression, irritability, anxiety, temporary depression, and 
dizziness (Efron et al., 1997).  Many pediatric patients are not treated with these 
medications due to the risk of side effects (Meijer et al., 2009).  Additionally, 
pharmacotherapy treatments are ineffective in as many as 25% of patients 
(Niederhofer, 2010).  Consequently, doctors and parents are seeking alternative 
therapies that provide patients with long-term relief from ADHD symptoms.  
The relationship between diet and ADHD symptoms is one possible target of 
non-pharmacological therapy.  Certain food additives, such as artificial food coloring, 
have caused or heightened the symptoms of behavioral disorders, including ADHD, 
in some individuals (Tuormaa, 1994).  The specific food additive studied in this 
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experiment is tartrazine, commonly known as Yellow #5.  This study explores 
relationship between dietary tartrazine intake and the biochemical and behavioral 
symptoms of ADHD.  
Team ATTENT completed a multi-phase study to evaluate the effects of 
dietary tartrazine on ADHD-associated behaviors, hyperactivity and impulsivity, as 
well as to determine its effect on brain dopamine concentrations in rats.  The chosen 
rats for this study were Spontaneously Hypertensive Rats (SHR), which are 
characterized by symptoms of inattentiveness, hyperactivity, and impulsivity, making 
them an ideal rat model for studying ADHD (Pires et al., 2010).  
The experiment was initiated with a thirty-day period of daily tartrazine 
administration through the rats’ diets.  Rats were divided into four experimental 
groups—control, low dosage, medium dosage, and high dosage—with different 
dietary tartrazine concentrations for each group.  Beginning on the 26th day of the 
treatment period, ADHD-associated behaviors were gauged using an open field test 
and a T-maze for four consecutive days.  These tests were conducted to look for 
behavioral differences between experimental groups.  
On the 30th day of tartrazine administration, the rats were euthanized, and 
their brain tissue underwent biochemical analyses.  This phase of the experiment 
sought to answer the question: How does increasing dietary tartrazine impact the 
expression of dopamine in the brain?  Brain tissue and blood were collected from 
each rat. An Enzyme-linked Immunosorbent Assay (ELISA) was used to estimate the 
amount of dopamine found in the various brain quadrants.  It was hypothesized that 
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increased dietary tartrazine increases expression of ADHD symptoms and decreases 






Dopamine is a monoamine neurotransmitter that is released by interneurons 
and has both regulatory and modulatory effects.  In the formation of dopamine, 
tyrosine hydroxylase (TH) adds a hydroxyl group to tyrosine, forming L-3,4-
dihydroxyphenylalanine (L-DOPA).  L-DOPA is then converted by DOPA-
decarboxylase to form dopamine.  Dopamine can then be converted to norepinephrine 
through the addition of a hydroxyl group on the β-carbon when catalyzed by 
dopamine β-hydroxylase.  Norepinephrine can later be used to synthesize epinephrine 
when catalyzed with phenylethanoloamine (Kuhar et al., 1999).  Dopamine generally 
acts upon five distinct classes of receptors.  D1 receptors activate the enzyme 
adenylate cyclase.  This enzyme forms cAMP, generating a secondary messenger 
cascade when dopamine acts on the receptor.  D5 receptors also increase the 
concentration of cAMP through other methods (Wu et al., 2012).  D2 receptors inhibit 
adenylate cyclase, thus inhibiting the secondary messenger cascade (Snyder, 2011).  
D3 and D4 receptors decrease the concentration of cAMP in the cell (Wu et al., 
2012).  The dopamine transporter, which is also referred to as the dopamine active 
transporter, is the protein that is responsible for transporting dopamine from the 
synapse into the cytosol.  Therefore, the level of dopamine that is present at the 
synapse between neurons and at the receptors of postsynaptic neurons is regulated 




Dopamine acts in three distinct systems that have varied effects on an 
individual’s behavior.  These systems include the nigrostriatal system associated with 
motor function, the mesolimbo-cortical system associated with the reward circuit, and 
lastly the tuberinfundibular system associated with hormone secretion (Keltikangas-
Jarvinen & Salo, 2009).  Extensive research has been conducted in the nigrostriatal 
system after it was discovered that a depletion of dopamine is commonly found in the 
caudate nucleus of Parkinson’s disease patients (Snyder, 2011).  Research has also 
been conducted to understand the link between dopamine and the efficacy of anti-
psychotic drugs.  These drugs generally block dopamine reuptake and have been 
considered most efficient when only blocking D2 receptors (Snyder, 2011).  
 Recently, dopamine has been implicated in the pathology of ADHD.  Since 
many ADHD patients have an altered sensitivity to reward and generally do not 
modify their behavior when rewards change, it has been hypothesized that ADHD is 
due to a disruption in the reward circuit (Volkow et al., 2009).  Dopamine is released 
in this circuit when the individual receives an unexpected award, thus allowing the 
individual to learn and modify behavior in order to continue receiving the reward 
(Schultz, 2002).  Furthermore, drug addiction is mediated by an increase in dopamine 
transmission (Schultz, 2002).  For individuals with ADHD, there is a decrease in 
D2/D3 receptors as well as dopamine availability in the mesolimbo-cortical system – 
more specifically in the left ventral caudate, accumbens and midbrain regions 
(Volkow et al., 2009).  The decrease in dopamine is correlated with a rise in ADHD 
related symptoms, including inattention (Volkow et al., 2009).  Other dopamine-
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related symptoms of ADHD include a decrease in working memory and motor 
control, as well as an increase in internalization of speech (Levy & Swanson, 2001).   
Genetic studies have shown that there might be a link between dopamine 
associated genes and ADHD.  Polymorphisms in at least two dopamine genes, drd4 
and dat1, are highly associated with ADHD (Levy & Swanson, 2001).  A highly 
polymorphic dinucleotide repeat of dopamine gene drd5 has also been associated 
with ADHD, and hyperactivity has been correlated with a certain variation of 
dopamine gene drd2 (Wu et al., 2012).  Additionally, a branch of research has 
determined that there are physical differences between the brain of an individual with 
ADHD and one without ADHD.  This difference affects dopamine transport in 
specific areas of the brain, including the frontal cortex, basal ganglia, and striatal 
system (Levy & Swanson, 2001).  Furthermore, there is a high comorbidity between 
Th1- and Th2- mediated disorders.  Mice deficient in Stat-6, a transcription factor in 
Th2 cells, demonstrate an increase in hyperactivity as well as a decrease in striatal 
dopamine transporter, both of which are common symptoms of ADHD (Verlaet et al., 
2014).  Dopamine has been heavily implicated in ADHD regarding a variety of 
factors ranging from an individual’s genetics to immune system.  Although the extent 
of how each of these factors affects ADHD is still unknown, it is clear that ADHD is 
correlated to a decrease in neural dopamine. 
Many of the drugs that are currently used to treat ADHD focus on increasing 
the production of dopamine.  ADHD medication inhibits either dopamine or 
norepinephrine reuptake, thus increasing the amount of available dopamine in the 
brain (Tripp & Wickens, 2012).  Specific norepinephrine reuptake inhibitors can 
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selectively increase dopamine concentrations in areas such as the prefrontal cortex, 
which is involved in the reward circuit, without affecting dopamine levels in the 
entire brain (Tripp & Wickens, 2012). 
The link between tartrazine, dopamine, and ADHD is not the only instance in 
which nutrition has been shown to influence ADHD symptoms.  For example, the A1 
allele, which codes for D2 dopamine receptor Taq 1A, is associated with Type 2 
Diabetes (Barnard et al., 2009).  ADHD and binge eating are comorbid, and many of 
the medications that are used to treat ADHD are also effective in modulating 
abnormal eating practices (Cortese et al., 2007).  Additionally, there have been 
multiple studies showing high-fat diets have resulted in an increase in expression of 
many of the genes that regulate dopamine (Lee et al., 2010) such as D2 receptors 
(South & Huang, 2008).  
The process of studying the effects of dopamine on ADHD in human brains 
requires a combination of neuroimaging and behavioral tests.  In one study, 
researchers took positron emission tomography (PET) scans of participants focusing 
on dopamine receptors and areas of high dopamine concentrations (Volkow et al., 
2009).  Functional magnetic resonance imaging (fMRI) and magnetic resonance 
imaging (MRI) are also common techniques to determine brain function as well as 
areas of high dopamine concentration (Volkow et al., 2009).  In order to rate the 
behavioral symptoms of ADHD, researchers often score individuals based on DSM-
IV guidelines or use questionnaires such as the Strengths and Weaknesses of ADHD-
symptoms and Normal-behavior (SWAN) scale (Volkow et al., 2009).  Researchers 
can also observe specific behaviors through a series of tasks including the “stop and 
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go” paradigm where participants are given a task and then told to stop in order to test 
the participant’s inhibitory control (Levy & Swanson, 2001).  By using a combination 
of measures, researchers correlate differences in dopamine and its receptors to 
behavioral symptoms of ADHD. 
Studying dopamine in animal models is essential for researchers to draw 
inferences about dopamine and its effects on ADHD.  One rat model used to study 
ADHD is the dopamine transporter knockout mouse (DAT-KO), which exhibits 
symptoms of ADHD such as hyperactivity.  In another study, rats of a different 
ADHD model were given one of three different dosages of intranasal dopamine and 
then asked to navigate a radial maze (Ruocco et al., 2009).  The results showed that 
the highest dose of dopamine reduced hyperactivity, while the intermediate dose of 
dopamine led to increased attention (Ruocco et al., 2009).  Rats have also been used 
to display that a low density of D5 dopamine receptors in the hippocampus are highly 
correlated to some of the learning difficulties that are observed in ADHD patients 
(Medin et al. 2013).  Common rat models of ADHD, including the SHR and Wistar-
Kyoto (WKY) rats, exhibit increased dopamine uptake providing evidence to suggest 
connections between dopamine and behaviors associated with ADHD (Miller et al., 
2012).   
 
Dopamine-rich Areas of the Brain 
The quantification of dopamine requires knowledge of the locations of 
dopamine-rich areas in the brain. These areas will be relatively rich in dopaminergic 
neurons compared to other areas in the brain, as the neurons release dopamine as the 
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primary neurotransmitter.  Although they correspond to less than one percent of total 
brain neurons, dopaminergic neurons play a significant role in the normal functions of 
various organ systems and are most notable for their role in mental and neurological 
disorders such as schizophrenia and drug addiction (Chinta et al., 2005). In the 
mammalian central nervous system, the major source of dopamine originates from 
dopaminergic neurons in the mesencephalon, or midbrain, which contains 
approximately 90 percent of the total number of brain dopaminergic cells (Chinta et 
al., 2005).  
 
Figure 1: Regions of the brain (Rice University, 2000) 
As a result, the study focuses on midbrain structures and their closely related 
projections to most representatively quantify dopamine in the whole brain.  Also, the 
noted structures may provide the basis for potential hypotheses that attempt to explain 
the link between ADHD and decreased dopamine in the brain of patients.  Structures 
in two dopaminergic pathways are of interest for this study due to their implication in 
dopamine-associated ADHD symptoms.  The nigrostriatal pathway, which plays a 
role in controlling voluntary movement, originates in the substantia nigra whose 
neuronal fibers extend to the striatum (Chinta et al., 2005).  The mesolimbic pathway, 
which plays a role in motivation, reward, and emotion based behavior, originates in 
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the ventral tegmental area (VTA) whose neuronal fibers project most prominently to 
the nucleus accumbens (Chinta et al., 2005).  The four areas mentioned are of interest 
in order to quantify dopamine.  
 
Figure 2: Dopaminergic pathways (Chinta et al., 2005) 
Substantia Nigra 
The substantia nigra is a large pigmented cluster of neurons located in the 
anterior midbrain in both hemispheres of the brain (Luijkx et al.).  As a component of 
the extrapyramidal system, the substantia nigra is involved in the modulation and 
regulation of movement (Luijkx et al.).  In the substantia nigra, dopaminergic neurons 
correspond to approximately three to five percent of the total neurons in the region 
(Chinta et al., 2005).  Consequently, the substantia nigra also plays a role in reward 




Figure 3: Lateral view (Speert, 2006) and aerial view (Medline Plus, 2015) of 
substantia nigra 
There are two parts that make up the substantia nigra: the pars compacta and 
pars reticulata.  The pars compacta consists of neurons that contain the dark pigment 
melanin and function primarily to synthesize dopamine and supply this dopamine to 
either the caudate nucleus or putamen, both of which are structures included in the 
striatum (Midbrain anatomy).  By supplying dopamine to the striatum via the 
nigrostriatal pathway, the substantia nigra mediates movement and motor 
coordination.  The pars reticulata conveys output signals to various other brain 
structures such as the thalamus (Midbrain anatomy).  
The most well-known neurodegenerative disease linked to the substantia nigra 
is Parkinson’s disease.  Parkinson’s disease is caused by the degeneration of 
dopaminergic neurons localized mostly in the substantia nigra pars compacta (Di 
Muzio et al.).  Significant loss of dopaminergic neurons in the substantia nigra pars 
compacta will cause subsequent depletion of dopamine in the striatum. Without the 
relay of dopamine, Parkinson’s disease presents as a movement disorder 
characterized by slowness of movement, tremor, rigidity, and loss of postural control 
(Chinta et al., 2005). 
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A lesser-known concept, however, is the role the substantia nigra may play in 
causing ADHD in children.  Scientists have hypothesized that the nigrostriatal 
dopaminergic system is structurally altered in children with ADHD.  In a study 
conducted in 2010, Romanos et al. investigated the echogenicity of the substantia 
nigra as a potential marker for the nigrostriatal dysfunction in children with ADHD. 
Echogenicity is the extent to which a structure is able to give off reflections of 
ultrasonic waves, or the extent to which a structure is able to appear in an ultrasound 
image (Dorland’s Medical Dictionary, 2007).  Using transcranial sonography, 
researchers used an ultrasound device to view and then manually circle the outer 
circumference of the substantia nigra in 22 children with ADHD and 22 healthy 
controls.  After quantification of an echogenic area, researchers found that the 
substantia nigra area was significantly larger in ADHD patients than in healthy 
controls.  Normally, echogenicity of the substantia nigra shows a gradual postnatal 
decline; thus, the increased echogenicity in children with ADHD implicates a 
developmental delay in this region.  In addition, the increased echogenicity of the 
substantia nigra has been associated with impaired uptake of dopamine.  Overall, this 
evidence supports the notion that in children with ADHD, there are structural and 
functional maturational delays in specific brain regions related to dopamine activity. 
Striatum 
The striatum is a cluster of structures that lies deep in the subcortical region of 
the forebrain and is a component of the interconnected grey matter in the brain called 
the basal ganglia.  Functionally, the striatum serves as an integration center for 
dopaminergic and glutamatergic inputs coming from various regions of the brain such 
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as the midbrain (where the substantia nigra lies), the thalamus, and the cortex (Baez-
Mendoza et al., 2013).  After integrating multiple inputs, the striatum then relays this 
information to other structures of the basal ganglia where actions such as learning and 
movement are mediated (Baez-Mendoza et al., 2013).  The striatum is a necessary 
neuronal circuit for voluntary movement control, but it is also a critical component of 
the reward system, specifically in social situations. 
 
 
Figure 4: Lateral view of striatum location (Fazzari) 
 The striatum is further divided into the dorsal and ventral striatum.  The dorsal 
striatum consists of the caudate nucleus and putamen and the ventral striatum consists 
of the nucleus accumbens (Knierim, 1997).  As mentioned before, the caudate 
nucleus and putamen are primary receivers of dopamine from the substantia nigra; 
thus, the dorsal striatum is involved in motor function.  The ventral striatum is 




Figure 5: Transverse slice of brain with striatal structures (Knierim, 1997) 
Similar to the substantia nigra, the striatum also shows abnormal function in 
children with ADHD.  Few studies exist that address ADHD and its connection to 
reward centers in the brain.  In a study conducted in 1989, Lou et al. researched 
cerebral blood flow distribution between patients with ADHD and healthy controls.  
The study concluded that striatal regions were hypoperfused and, by extension, 
hypofunctional because of the lack of circulating oxygen reaching the region.  While 
hypofunction of the striatum is an accepted aspect of ADHD, a more recent study 
conducted by Carmona et al. in 2009 investigated the structural aspect of the striatum 
in patients with ADHD.  The researchers compared the volumetric difference between 
the ventral striatum in 42 children with ADHD and 42 healthy control subjects 
matched by factors such as age, gender, and handedness.  The study revealed that 
ADHD patients had lower ventral striatum volumes than their control counterparts, 
showing an average of a 25.28% decrease in the volume of the left and right striatal 
regions after being corrected for total blood volume.  The decrease in ventral striatum 
volume also correlated with poor symptoms of hyperactivity and impulsivity.  Both 
studies mentioned above give more insight into the pathophysiology of ADHD.  
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Ventral Tegmental Area 
The ventral tegmental area, or VTA, is a dense cluster of structures located 
close to the substantia nigra within the midbrain.  The region is a part of the 
mesolimbic and mesocortical pathways.  The mesocortical pathway connects the 
VTA to the cortical areas in the brain’s frontal lobes.  The mesolimbic pathway, of 
interest to this research, connects the VTA and the nucleus accumbens (Russo & 
Nestler, 2013).  This pathway is part of a reward circuit.  Dopamine is released from 
the VTA and travels to the nucleus accumbens in response to reward or aversion-
related stimuli.  Pleasurable activities and psychostimulant drugs stimulate this region 
of the brain and make it especially relevant to the study of addiction (Center for 
Bioinformatics).   
Prior research suggests that the neurons within the VTA play an important 
role in learning and motivation through their communication with the nucleus 
accumbens, prefrontal cortex, and amygdala (Saunders & Richard, 2011).  A current 
clinical study at Duke University is examining VTA activation and goal-directed 
motivation through a series of magnetic resonance imaging (MRI) sessions.  The 
study links low VTA activation with aggravated symptoms of ADHD and attempts to 
lessen these symptoms and improve motivation through non-medication intervention 
(Kollins & Itchon-Ramos, 2016). 
Nucleus Accumbens 
The nucleus accumbens is a cluster of neurons located in the forebrain.  This 
region of the brain plays an important role in reward, addiction, and pleasure.  
Located at the end of the mesolimbic pathway, the accumbens receives dopamine 
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from the ventral tegmental area.  Other inputs to the nucleus accumbens include the 
prefrontal cortex, amygdala, and hippocampus (Center for Bioinformatics).  
The terminals between the VTA and nucleus accumbens are the action site for 
drugs such as cocaine and amphetamine.  Because addictions to food, sex, and drugs 
are implicated with dramatic increases in dopamine, the nucleus accumbens is 
essential to understanding the neurochemical mechanisms behind addiction (Center 
for Bioinformatics).  One study conducted using a rat model discovered that 
impulsivity significantly increased when the nucleus accumbens was altered or 
damaged.  Impulsivity was induced in the rats by creating lesions in the core of the 
nucleus accumbens (Cardinal et al., 2001).  
Scientists at Universitat Autonoma de Barcelona examined the brains of 
children with ADHD using magnetic resonance imaging (MRI).  The scans revealed 
anomalies in the brain’s reward system in the ADHD brains compared to the normal 
brains.  Children with ADHD exhibited reduced volume in the nucleus accumbens 
region and these differences were associated with hyperactivity, impulsiveness, and 
deficiencies in motivation (Nauert, 2015). 
Circadian Control of Dopamine 
The superchiasmatic nuclei (SCN) located at the base of the hypothalamus is 
the main circadian pacemaker in mammalian brains (Mendoza & Challet, 2014).  The 
SCN is synchronized to solar time, as light is transmitted by the retina the SCN will 
regulate the necessary hormonal and nervous pathways.  One of these pathways 
controls the circadian rhythm of dopaminergic activity.  The activated SCN will act 
through the orexinergic (ORX) and medial preoptic nucleus (MPOA) neural pathways 
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to activate dopamine production in the VTA and substantia nigra.  The regulation of 
dopamine in the brain is thus affected by the light/dark cycles in human environment.  
Dopamine will then impact motor activity and motivation.  
In a study by O’Neill and Fillenz (1985), the pattern of dopamine release in 
the frontal cortex, striatum, and nucleus accumbens was monitored.  It was found that 
there was no correlation between the amount of dopamine released and time of day in 
the frontal cortex as there is little feedback regulation of the dopamine release.  
However, dopamine release in both the nucleus accumbens and striatum is highly 
regulated by feedback mechanisms.  As rats are nocturnal there was a significant rise 
in dopamine release at night (O’Neill & Fillenz, 1985).  
Rat Model 
The rat model used in this study is the SHR model, which is frequently used to 
emulate ADHD in a laboratory setting.  This model is helpful in studying ADHD 
because the rats mirror many of the neurochemical and behavioral symptoms found in 
human ADHD (Pires et al., 2010).  In addition, the SHR often exhibits cognitive 
difficulties when performing tasks in a manner that is consistent with ADHD.  
Because of the rat’s natural tendency to demonstrate cognitive impairment, the SHR 
model is of interest in studies involving the reduction of ADHD symptoms to 
improve mental functioning (Pires et al., 2010). 
In one study, the SHR model and a close genetic strain, the Wistar Kyoto 
(WKY) rat model were both tested to determine if long-term caffeine treatment 
during prepubescence would improve cognition in later stages of life (Pires et al., 
2010).  The SHR model exhibited many cognitive deficiencies prior to treatment, but 
 19 
 
after caffeine treatments, these symptoms improved.  The WKY rat model, however, 
did not have many cognitive difficulties before treatment, but after caffeine treatment, 
the WKY rats exhibited impaired ability to discriminate between objects and 
complete tasks (Pires et al., 2010).  The authors suggested that the WKY rat model 
would be a better indicator of a non-ADHD population, while the SHR model could 
be used to replicate ADHD in an experiment.  A young SHR of around 3-4 weeks of 
age would also exhibit symptoms found in juvenile ADHD (Pires et al., 2010).  
The use of the SHR as a model of ADHD is supported by several other 
studies, one of which looked at the effects of microdialysis treatment for ADHD on 
both SHR and Sprague-Dawley (SD) rats (Heal et al., 2008).  SD rats were previously 
used as the basis for ADHD in various studies of pharmacological drugs.  The SHR 
was used in this study due to the fact that hyperactivity and impulsivity develops prior 
to the hypertension that is observed around ten weeks of age and older.  However, it 
should be noted that ADHD-like symptoms in the SHR rat persist through maturity 
(Heal et al., 2008).  The SHR rats were shown to exhibit the dopaminergic phenotype 
of ADHD in humans better than the SD rats (Heal et al., 2008).  Another study that 
concluded that the SHR model is the only one that accurately models the behavioral 
symptoms of ADHD including increased hyperactivity and attention deficits 
(Sagvolden, 2000).  Heal et al.’s (2008) study is just one of many, such as Pires et 
al.’s (2010), that supports the decision to use the SHR by providing evidence that the 




The SHR also demonstrates similar neural dopamine patterns as do humans 
with ADHD.  When compared to other ADHD rat models, there seems to be 
increased levels of dopamine in the synaptic cleft of SHRs (Viggiano, 2004).  There 
is also an increase in D2-mediated inhibition of dopamine release in the striatum 
(Oades et al., 2005).  It has also been discovered that D1 and D2 receptors are 
overexpressed in the striatal and frontal regions of the SHR (Russel, 2002).  Recently, 
an overexpression of dopamine transporter (DAT) was found in the caudate nucleus 
and striatum of the SHR than the WKY rat model (Miller et al., 2012).  Although 
there is an increase in DAT, these transporters are hypofunctional, resulting in a 
decrease in dopamine reuptake (Viggiano, 2004).  The reduction of dopamine 
reuptake by DAT has also been linked to reduction in actual dopamine release from 
axons terminals (Viggiano, 2004). 
 There has also been past experimentation on SHR through which researchers 
have been able to manipulate brain dopamine in the rats based on the addition of 
ADHD treatment options.  Researchers have given SHRs amphetamines and 
methylphenidates, both drugs commonly prescribed as ADHD medication, and they 
discovered an increase in dopamine in the rats’ brains (Carboni et al., 2003).  
Specifically, there was a significant increase in extracellular dopamine in the nucleus 
accumbens (Carboni et al., 2003).  Since amphetamines increase dopamine release 
while methylphenidates block dopamine reuptake, it is evident that both drugs 
increase extracellular dopamine concentrations (Carboni et al., 2003).  As a result, the 
SHR’s reaction to the drugs is consistent with how human ADHD patients would 
react.  On the other hand, when SHR were dosed with caffeine, the rats showed an 
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improvement in memory and attention deficits and displayed normalized dopamine 
levels (Pandolfo et al., 2013).  There was a decrease in DAT function in the frontal 
cortex, which led to higher extracellular dopamine concentrations (Pandolfo et al., 
2013).  Although caffeine is still not a treatment used in humans, the inverse 
relationship between ADHD symptoms and neural dopamine concentration found in 
the rats is similar to the relationship evident in humans.  The rat models that were 
used in this study were rats that modeled ADHD behaviors as opposed to a typical 
wildtype lab rat, or one that behaved “normally”.  This is because the study focused 
on how the ADHD symptoms worsened in the rat, rather than inducing the ADHD 
symptoms in the rats. 
 
Food Additives 
This experiment sets out to test the hypothesis that certain food additives will 
negatively affect the symptoms of ADHD, thus helping identify a specific connection 
between the diet and neurobiological and behavioral symptoms of ADHD.  As a 
result, specifically looking at the effects of food additives on the symptoms of ADHD 
can help determine the potential benefits of a restriction diet.   
Currently, there are about 3,794 different types of food additives used in our 
food, and on average, 200,000 tons of these food additives are used per year 
(Tuormaa, 1994).  The increased reliance on food additives to preserve, color, and 
improve the taste of food leads to the estimate that “each person is now consuming an 
average 8-10 lbs. of food additives per year, with some possible eating considerably 
more” (Tuormaa, 1994). 
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A fundamental concept that supports the need for understanding the effects of 
food additives on ADHD is the Feingold Hypothesis.  In 1973, Dr. Benjamin 
Feingold of the Department of Allergy at the Kaiser Permanente Foundation Hospital 
and Permanente Medical Group in San Francisco, proposed that hyperactivity in 
children stemmed from the use of food additives (Stevens et al., 2011).  Feingold 
proposed, “low molecular weight compounds, like artificial food dyes, can produce 
behavioral disorders in susceptible individuals” (Tuormaa, 1994).  This striking 
conclusion came from his studies on over 1,200 cases where he found that children 
who consumed certain chemicals, including particular food additives and natural 
salicylates, showed signs of hyperactivity and other neurophysiological disturbances. 
Approximately 30% to 50% of children who exhibited ADHD symptoms could be 
treated by restricting foods that contain certain food additives and natural salicylates 
(Tuormaa, 1994).  Although Dr. Feingold’s findings appear to show a very simple 
and straightforward correlation, there is still much to be learned and explored when it 
comes to the relationship between food additives and their effect on ADHD 
symptoms.  Since Feingold’s discovery, a multitude of diets have been developed, 
many of which, like the Kaiser-Permanente Diet (K-P Diet), recommend that those 
diagnosed with ADHD refrain from consuming natural salicylates, artificial food 
colorings (AFCs), and artificial flavors (Stevens et al., 2011).  Even with its 
widespread use, there has been little evidence to show the definitive effectiveness of 
the K-P Diet.  Approximately 11% to 33% of children responded to this with changes 
in ADHD symptoms, yet the biochemical cause of these changes is not understood 
(Stevens et al., 2011).  Various countries have started to put sanctions on the types of 
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artificial food dyes that are permitted in food production.  For example, the European 
Parliament banned the usage of tartrazine in food production in 2009 (European Food 
Safety Authority).  Due to the increasing reliance on food additives, it is important to 
further explore the connection between food additives and behavioral disorders. 
Tartrazine 
Of the total 3,764 food additives, the food additive that will be the focus of 
this research is tartrazine, whose structure is shown in Figure 6.  Tartrazine is a 
yellow food coloring that is common in the American diet.  It is popular in processed 
foods such as candy, sports drinks, and soft drinks.  
 
Figure 6: Chemical structure of tartrazine (Tartrazine) 
Officially called E-102, Yellow #5 dye, tartrazine is a synthetic organic 
chemical that serves as a lemon yellow azo dye.  This water soluble substance has the 
official chemical name: trisodium-5- hydroxy-1-(4-sulfonatophenyl)-4-(4-
sulfonatophenylazo)-H-pyrazole-3-carboxylate (Gao et al., 2011).  Due to the 
presence of an azo group—two nitrogen atoms double bonded to each other—
tartrazine can be detrimental in high quantities (Gao et al., 2011).  This nitrous 
compound is highly sensitizing in the body, causing hypersensitivity, allergic 
reactions, and mutagenesis (Moutinho et al., 2007).  The acceptable daily intake 
(ADI) of tartrazine is between 0 - 7.5 mg/kg/day (Moutinho et al., 2007).  However, it 
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is highly recommended that children only consume 37.2% of the maximum 
theoretical intake of 7.5 mg/kg/day (Elhkim et al., 2007).   
The accepted daily intake (ADI) level of 7.5 mg/kg/day was established by 
performing dose-response studies in animal models. By administering varying doses 
of the substance to laboratory animals, scientists look for the smallest dose that causes 
any detectable effect on organs, behavior, or body chemicals (Foundation for 
American Communications). This level, called the Lowest Observable Effect Level 
(LOEL), is specific to the toxicity imposed on laboratory animals. Another measure 
scientists obtain from dose-response studies is the No Observable Effect Level 
(NOEL); this is the highest dose at which no effects occur (Foundation for American 
Communications). The NOEL is the “safe level” for a chemical in the specific species 
studied. The NOEL is the value of interest when determining the “safe level” for 
humans. In order to apply this value to humans, public health officials usually divide 
the NOEL by a safety factor, usually 100, to determine a “safe level” for humans 
(Foundation for American Communications). This factor accounts for differences 
humans may experience with regards to a human’s sensitivity to the substance and 
variability in the genetics, health, and age of humans that may affect the response to 
the substance being studied. For example, the NOEL determined for tartrazine in 
dose-response studies in a laboratory animal would be 750 mg/kg/day; thus the “safe 
level” for humans translates to an ADI of 7.5 mg/kg/day. In general, it is thought that 
determining “safe levels” in this manner yields a level that is likely lower than the 
true NOEL for humans, but risk managers agree to use this value in regulatory policy. 
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While about only 2% of ingested tartrazine is directly absorbed by the body, 
most tartrazine is broken down into smaller metabolites in the colon (Elhkim et al., 
2007).  Tartrazine reduction is facilitated by intestinal bacteria that release electron 
carriers in the anaerobic environment of the colon (Elhkim et al., 2007).  Extracellular 
electron acceptors in these conditions allow for azo dye reduction into nitrous 
metabolites such as aminopyrazolone and 4-hydrazinobenzenesulfonic acid which can 
be further reduced to sulfanilic acid (Elhkim et al., 2007).  While parent tartrazine is 
absorbed at a much lower incidence, the body readily absorbs these metabolites.  
Consequently, it is believed that the metabolic byproducts of tartrazine are the 
substances causing sensitivity and adverse reactions in the body.  
The harmful nature of tartrazine most notably stems from the chemical’s 
transformation into an aromatic sulfanilic acid after being digested by gastrointestinal 
microflora (Moutinho et al., 2007).  Sulfanilic acid is the main metabolite of 
tartrazine and its structure is also a nitrous derivative, meaning this byproduct equally 
contributes to the risks associated with consuming food colorings.  
Most sulfanilic acid travels through the gastrointestinal system and is released 
in fecal matter.  Smaller amounts of tartrazine, the parent molecule of sulfanilic acid, 
are released in feces.  Electron receptors found in the body aid in the reduction of 
tartrazine into sulfanilic acid, facilitating improved metabolite excretion (Elhkim et 
al., 2007).  In one study, sulfanilic acid was administered to postnatal rats via an 
intraperitoneal injection to examine its impact on behavior (Goldenring et al., 1982).  
Researchers observed hyperactivity and impairment of performance in shock escape 
activities in the sulfanilic acid rats.  The research team refrained from extrapolating 
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the data to children or adult humans due to differences in the blood-brain barrier and 
absorption between the two species (Goldenring et al., 1982).  
While the Food and Drug Administration (FDA) allows tartrazine in the 
United States, the European Parliament has banned tartrazine from all food 
production (Jacobson, 2010).  Additionally, The Center for Science in the Public 
Interest (CSPI) and European food safety officials have warranted studies linking 
food dyes to childhood hyperactivity and behavioral problems as sufficient evidence 
to ban certain food dyes.  The CSPI has urged the FDA to follow their ban on certain 
food dyes (Jacobson, 2010). Before the banning of tartrazine in European food, 
studies that compared the rates of ADHD diagnosis in the United States versus 
European countries concluded that the prevalence of ADHD in the US is not 
significantly higher than those in Europe (Faraone et al., 2003; Polanczyk et al., 
2007).  There has been no comparison test published after the ban. 
Tartrazine may be relevant to ADHD studies, as it appears to have a zinc 
wasting effect in some hyperactive children (Stevens et al., 2005).  In one notable 
study, scientists found that tartrazine increased urinary zinc excretion in children that 
were hyperactive when compared to a control group (Tuormaa, 1994).  Interestingly, 
it has been proposed that zinc depletion is a cause of childhood hyperactivity since 
zinc can act as a cofactor in the metabolism of neurotransmitters (Tuormaa, 1994; 
Stevens et al., 2013).  Zinc is also needed for the production of melatonin, which 
helps to regulate dopamine function (Arnold & DiSilvestro, 2005).  This suggests that 
tartrazine consumption and dopamine expression may be linked. 
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There appears to be a gap in research regarding the biochemical or 
physiological mechanisms by which food additives affect ADHD symptoms.  As a 
result, this study aims to track biochemical changes in the body in response to 
tartrazine ingestion and pinpoint these changes as possible causes of ADHD-like 
symptoms.  While there is much speculation that food colorants such as tartrazine 
contribute to ADHD-like symptoms, the exact biochemical mechanism is not known. 
To reason with this ambiguity, this study took accepted premises about ADHD and 
food colorings to form the basis for research.  As indicated before, it is suggested that 
dopamine levels are lower than expected in patients with ADHD.  Since tartrazine 
may exacerbate ADHD symptoms, this study aims to study the relationship between 





This mixed methods study aims to assess a dietary aspect that may affect 
ADHD symptoms.  The SHR is used to address the relationship between a nutritional 
factor, such as food additives, and neurochemicals in the brain that lead to an increase 
in ADHD symptoms.  This information was compiled to perform a qualitative and 
quantitative experiment on rats.  The experiment utilizes quantitative data in the 
measurement of biochemical results and qualitative data for behavioral and survey-
based observations.  This qualitative aspect aims to support calculated quantitative 
data by showing the effect of the biochemical aspect of the experiment on observed 
behavioral changes. 
           The study of ADHD and its associated treatments currently displays 
inconsistencies and aspects requiring increased research.  The use of 
pharmacotherapy has demonstrated effectiveness in treatment for some patients, 
while others remain unaffected or negatively affected by these drugs.  Furthermore, 
there is an exhibited desire among patients and parents of patients for alternative 
treatments to ADHD.  In one study conducted, 68% of participants investigated 
complementary and alternative methods (CAM) to pharmacological treatments (Sinha 
& Efron, 2005).  Many medical professionals also concur that alternative treatments 
would be best in supplementation to pharmacological treatments (Sinha & Efron, 
2005).  The research completed by this project can impact these missing components 
of ADHD treatment and management.  Furthermore, the potential work with food 
additives of this project can contribute to methodologies used in the study of their 
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biochemical effects since not much work has been done on animal models.  In 
summary, both the conceptual results of this project and the methodological 
techniques utilized can make an impact in the aspects of ADHD treatment and 
nutritional research that are lacking a strong database and foundation of knowledge. 





The review of literature pertaining to ADHD and nutrition led to Team 
ATTENT’s research question regarding the biochemical and behavioral impacts of 
tartrazine consumption.  The following methodology was used to support the 
hypothesis that dopamine levels will decrease in the SHRs, which will cause an 
increase in expression of the ADHD symptoms of hyperactivity and impulsivity with 
increasing concentrations of dietary tartrazine. 
Housing and Care of Animals 
The rats were housed individually in stainless steel grated metal cages.  The 
room had 100% ventilation, receiving a constant supply of fresh air, and was kept at a 
constant 72 degrees Fahrenheit and 45% humidity.  The room was kept at a standard 
12 hour light/dark cycle with lights on at 0800 hours.  Standard husbandry procedures 
such as changing bedding, collecting bodily waste as well as spillage, recording body 
weight and room temperature, and giving general health examinations occurred on a 
regular basis (Abou-Ismail et al., 2007).  While these practices were necessary to 
keep the animals healthy, they could be stressful for rats and induce short-term 
changes in behaviors (Abou-Ismail et al., 2007).  In order to mitigate these behavioral 
changes, and thus limit possible stressful effects that general care can have on 
experimental results, husbandry procedures were done during the light phase of the 
light/dark cycle (Abou-Ismail et al., 2007).  Additionally, all procedures were 
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completed as quickly as possible to help mitigate the amount of stress to the animal.  
(Balcombe, Barnard, & Sandusky, 2004).  
A total of forty six-week-old male SHRs were purchased from Hilltop Labs 
(Smalltown, PA).  As shown in Table 1, a group of twenty rats (Group Alpha) was 
purchased first.  After 7 days of acclimation, these rats were strategically separated 
into dosage groups in order to have a similar average weight among the groups.  Each 
dosage group (control, low, medium, and high) consisted of five rats.  The rats drank 
tap water and ate a standard diet ad libitum.  Food intake and body weight was 
recorded daily throughout the duration of the study.  Tartrazine administration began 
on the 8th day, and after thirty days of tartrazine administration, this group of twenty 
rats was euthanized.  
A second group of twenty rats was obtained in one round of four rats (Group 
Beta) and two rounds of eight rats (Group Gamma and Group Delta).  These rats were 
allowed to acclimate for seven days.  Group Beta began training for impulsivity 
testing immediately following acclimation.  Tartrazine administration was conducted 
for 30 days after the completion of training for Group Beta, and behavioral testing for 
both hyperactivity and impulsivity began on day 26, lasting for the final four days.  
At the conclusion of 30 days, these rats were euthanized to undergo biochemical 
testing.  Groups Gamma and Delta were also allowed to acclimate for seven days. 
Then, tartrazine administration was conducted for 30 days, and hyperactivity testing 
began on day 26, lasting for the final four days.  These rats were also euthanized to 
undergo biochemical testing.  Table 2 details the individual identities of each rat test 
subject and their corresponding tartrazine dosage group in Groups Alpha-Delta.  
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Testing Sacrifice  
Alpha 11/04/2014-11/10/2014 
11/11/2014-


















Table 1: Experimental timeline for rat Groups Alpha-Delta 
 
 Rat IDs 
Group Control Low Dosage Medium Dosage High Dosage 
Alpha 1, 2, 3, 4, 5 6, 7, 8, 9, 10 11, 12, 13, 14, 15 16, 17, 18, 19, 20 
Beta As Bs Cs Ds 
Gamma A, B C, D E, F G, H 
Delta  I, J K, L M, N O, P  






Standard tartrazine with a dye content concentration of ≥85 % was obtained 
from Sigma-Aldrich.  The tartrazine was in a solid, fine powdered state upon arrival. 
Tartrazine was the same consistency as the standard powdered rat food. Therefore, it 
was  mixed by hand with 1 kilogram of solid food powder for each dosage group to 
create the correct dosage amounts for each group.  
 The maximum amount of tartrazine acceptable for administration is 250 
mg/kg body weight for a rat, as this corresponds to a human dosage of 40 mg/kg body 
weight-the maximum amount of tartrazine a human would consume in a day (Yonglin 
et al., 2011).  In a study conducted by G. M. Hassan, a tartrazine dosage of 7.5 mg/kg 
body weight was used on Wistar rats to test for DNA damage (2009).  Drawing from 
studies by Yonglin et al. and Hassan, Team ATTENT utilized the following dosages 
of tartrazine: the low dosage was 0.05% tartrazine, the middle dosage was 0.15% 
tartrazine, and the high dosage was 0.45% tartrazine.  The control group received a 
dosage of 0% tartrazine.  The appropriate dosage was administered to each rat in food 
bowls, at the same time of day, for 30 days.  The food was weighed when given to the 
rats and weighed again the next day after 24 hours in order to track consumption.  
This procedure was repeated for 30 days. 
Behavioral Testing 
Behavioral testing of the second group of twenty rats was divided into two 
separate phases to test hyperactivity and impulsivity.  Group Beta rats underwent 
testing for impulsivity using a T-maze.  The approximate dimensions of the maze are 
61 cm x 10 cm x 39 cm, and the maze is fitted with two separate arms.  The T-maze 
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also had removable doors on each of the arms to control a rat’s access to a particular 
section of the maze (Mariano et al., 2009).  Hyperactivity was tested for Groups Beta, 
Gamma, and Delta with the use of an open field chamber.  The chamber measured 40 
cm x 40 cm x 30 cm (Fox et al., 2013). 
Testing for Impulsivity 
Impulsivity of Group Beta rats was tested using the T-maze impulsivity test.  
The T-maze had dimensions of approximately 61 cm x 10 cm x 39 cm (Mariano et 
al., 2009).  Each arm had a moveable door that closed behind the rat once the rat 
selected that arm.  Another door then opened to allow the rat access to the sugar 
reward placed at the end of the arm (Mariano et al., 2009).  After each trial, the T-
maze was wiped clean in order to reduce any scent that may affect arm selection in 
subsequent trials.  Impulsivity was measured in the times the rat opted for the smaller, 
more immediate reward versus the larger, delayed one (Mariano et al., 2009). 
 Once the first seven days of acclimation were completed, rats began receiving 
training for the T-maze impulsivity test.  In this apparatus, one arm contained a small 
reward of one pellet, and the other arm contained a large reward of five pellets 
(Mariano et al., 2009).  On each day of training, the rats were initially forced to 
choose each arm at least once, completing what is called a “forced trial”.  Only one of 
the arms of the T-maze was open at a time.  For example, if the rat was being guided 
to go into the small reward arm, then the door to the large reward arm was closed 
while the door to the small reward arm was open.  The rats then underwent 5 trials in 
which they could choose between the maze’s two arms.  These trials in which the rats 
had freedom of choice are called “choice trials”.  Training concluded for a rat when it 
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selected the arm with the greater reward at least four out of five times over two 
consecutive days (Mariano et al., 2009).  Rats were trained before tartrazine treatment 
in order to ensure that the treatment would not interfere with T-maze performance. 
 Starting on day 26 of tartrazine treatment, the rats underwent 12 trials for four 
consecutive days (Erickson et al., 2014).  Before each trial, the rats were allowed to 
eat and drink ad libitum.  At the beginning of each day, the rats underwent a forced 
trial to each arm of the maze and subsequently participated in ten choice trials 
(Mariano et al., 2009).  On the first day of testing, there was a five second delay until 
the rat received the larger reward.  The time that the rat needed to wait before 
receiving the larger reward increased by five seconds every day the experiment 
progressed.  Therefore, there was a ten second delay on the second day, a 15 second 
delay on the third day, and a 20 second delay on the final day.  After each choice trial, 
the arm the rat was recorded.  When impulsivity testing was complete, the average 
impulsivity for each dosage group was compared between groups.  Since we had a 
control group of rats that had not been treated with any tartrazine, we used this group 
as a baseline measurement, rendering it unnecessary to conduct impulsivity testing 
before tartrazine treatment.  A flowchart of impulsivity training and testing can be 
found in the Appendix C. 
Testing for Hyperactivity 
Beginning on day 26 of tartrazine administration each rat in Groups Beta, 
Gamma, and Delta was subjected to an open field test.  Each rat was individually 
placed into an open field chamber measuring 40 cm x 40 cm x 30 cm (Fox et al., 
2013).  The rat remained in the chamber for a trial period of 15 minutes, free to move 
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throughout the chamber during the trial.  Rats did not have access to food or water 
during this time (Fox et al., 2013). Each rat underwent one trial of the open field test 
each day for four consecutive days. This gives a total of four hyperactivity trials per 
rat.  A high definition camera was used to film each rat during each trial.  All film 
was analyzed and processed using an EthoVision XT 11 program by Noldus 
Information Technology.  Hyperactivity was evaluated utilizing video analysis to 
measure distance moved and velocity of movements (Fox et al., 2013).  The test 
subjects not receiving tartrazine treatment were used for baseline data to compare to 
the activity of the other subjects. 
Behavioral Video Analysis 
We used the Noldus EthoVision XT version 11.5 analysis to quantify the 
hyperactivity of the rats (Fox et al., 2013).  Noldus EthoVision is an automated 
program that has been previously used to analyze video data for certain parameters of 
SHRs in ADHD studies (Kim et al., 2012), including the parameter of the distance a 
rat moves in an open field test (Van den Bergh et al., 2006).  Once all the videos of 
our trials were collected, the program tracked the center of each rat’s body as the rat 
moved around, thus calculating the distance traveled and average velocity of each rat 
throughout the 15-minute period of each trial.  These values quantified the 
hyperactivity of a tartrazine receiving rat compared to a control rat.  The arena and 
tracking settings were reset specifically for each day of recording in order to ensure 





Brain Tissue Homogenization 
Whole brain samples taken from the test subjects were removed from storage 
in a -80˚ Celsius freezer and set to thaw for 15 minutes.  After thawing, the brain 
samples were prepared to be cut into quadrants.  Using a sharp blade, the following 
cuts were made to create four separate quadrants of the brain (Figure 7):  
 
Figure 7: On the rat brain pictured above (Kiernan, 2007), orange lines indicate the 
vertical and horizontal cuts that were made during brain sectioning to separate the 
brain sample into four quadrants. The circled blue regions indicate the general areas 
where the aforementioned dopamine rich areas of the brain are located. 
 
Each quadrant was labeled by its right or left and front or back location. The 
right and left front quadrants are expected to encompass the striatum and nucleus 
accumbens while the right and left back regions are expected to encompass the 
substantia nigra and ventral tegmental area. The weight of each individual quadrant 
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was measured and recorded.  Before the homogenization step, the brain quadrants 
needed to be suspended in a 1X Phosphate Buffered Saline (PBS) buffer.  Prior to 
beginning brain tissue homogenization, 1X PBS buffer was prepared and brought to a 
pH of 7.4—physiological pH—according to the following procedure: 
 
1. Dissolve 8 grams (g) of NaCl, 0.2g of KCl, 1.44g of Na2PO4 and 0.24g of 
KH2PO4 in 800 milliliters of distilled water.  
2. Adjust the pH to 7.4 with HCl if needed.  
3. Add water to bring total volume to 1 Liter.  
The recorded weight of each quadrant was multiplied by three, and the 
resulting number determined the milliliters of PBS buffer the quadrant was suspended 
in. Homogenization was performed using a Dounce homogenizer, also known as a 
tissue grinder.  The calculated volume of PBS buffer specific to each quadrant sample 
was transferred via pipette to the shaft of the homogenizer.  The sample brain 
quadrant was then added to the shaft.  The pestle of the homogenizer was used to 
homogenize the sample thoroughly.  The resulting liquefied sample was transferred to 
a microcentrifuge tube and then kept in storage in a -80˚ Celsius freezer.  
 
 







Samples were assayed for total protein concentration with a Bio-Rad 
spectrophotometric protein assay (Catalog number 5000001).  Dopamine 
concentration was subsequently assessed with an Enzyme-linked Immunosorbent 
Assay (ELISA) for rat dopamine purchased from My Biosource (Catalog number 
MBS725908).  This kit utilized the binding to anti-rat dopamine antibodies, which 
have a high affinity for rat dopamine, to determine the concentration of dopamine 
present in samples.  In order to assess and compare dopamine concentration between 
specimens and groups, dopamine concentration was normalized to total protein 
concentration. 
Statistical Analysis 
A power calculation was performed using predicted means and standard 
deviations, even sample sizes across test groups, and three test groups in addition to 
the control group.  The power calculation yielded a test group sample size of 5 rats 
given a power level of 0.80 and a Type I error rate of 5%. 
For each of the two replicate experiments performed, three major sets of 
biochemical data were analyzed.  These sets included the cumulative food intake, 
total measured brain dopamine, and total measured brain dopamine proportional to 
brain protein concentration.  Analysis of variance (ANOVA) was used to analyze all 
sets of data.  Independence, normality, and homoscedasticity were all assumed true. 
Only for Groups Gamma and Delta, behavioral analysis was also conducted.  Both 




It is important to eliminate or minimize the presence and effect of 
confounding variables in any research.  For the purposes of this project, examining 
body weights can provide insight into whether different dosages of tartrazine 
administration can have unanticipated but significant effects on food consumption 
behaviors or rat body metabolism, among other characteristics.  A lack of significant 
results would support the proposition that any observed significant results in 
measured brain dopamine are a direct consequence of tartrazine administration. 
Body weights were analyzed using ANOVA with four groups (n=5) assigned to 
control and test groups, with group assignments based on tartrazine concentration 
administered. 
Food Intake 
The purpose of analyzing cumulative food intake was to check for unexpected 
abnormalities and deviations that would suggest a confounding variable.  For 
instance, significant differences in food intake between test groups would suggest a 
relationship between the quantity of tartrazine consumption and behaviors associated 
with eating.  Lack of significance in analyses would indicate that any observed 
changes in brain dopamine should be solely a consequence of the tartrazine 
concentration administered. 
Cumulative food intake was analyzed using ANOVA with four groups (n=5) 
assigned to control and test groups in the same way as for body weights.  One data 
value for one of the rats from the experimental control group and one data value for 
one of the rats from the high dosage group were missing from data collection. 
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Subsequently, these two data points were omitted from the corresponding data set 
prior to ANOVA, and analysis for those given test groups and days using data from 
four SHRs.  Data was entered as a table with twenty rows and thirty columns, with 
each data point as food intake for one rat for one particular day during the thirty-day 
treatment period. ANOVA was conducted using SAS software.  Means and standard 
errors within each group were collected in addition to the F-value, p-value, and R-
squared value.  Duncan’s multiple range test, which controls for type I error, was 
used to analyze across groups (α = 0.05). 
Total Brain Dopamine 
As previously stated, dopamine can be used as a biochemical measure for 
ADHD.  Thus, analysis of the quantification of brain dopamine provides insight into 
potential biochemical effects of tartrazine on ADHD.  Total brain dopamine 
measurements were taken from ELISA results and entered into SAS for an ANOVA. 
Four groups (n=5) were assigned based on administered tartrazine dosage.  Means, 
standard errors, F-value, p-value, and R-squared value were returned from the 
ANOVA in addition to the results from a Duncan’s multiple range test. 
Dopamine Proportional to Protein 
Individual SHRs had brains that yielded different total quantities of brain 
dopamine and protein.  To account for discrepancies and differences between SHRs 
in brain protein, analysis was performed on the quantity of brain dopamine 
proportional to brain protein concentration, which will henceforth be denoted 
dopamine per protein.  Total brain protein concentration was obtained from the Bio-
Rad Bradford Protein Assay.  Total brain dopamine values for each SHR were 
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divided by the corresponding protein concentration obtain the dopamine per protein 
values, and these values were then entered into SAS as the data set for the ANOVA 
performed.  This ANOVA was also conducted with the same group assignments as 
the other ANOVAs.  As with cumulative food intake and total measured brain 
dopamine, means, standard errors, F-value, p-value, and R-squared value were 
computed, and a Duncan’s multiple range test was performed as well. 
Replicate Testing 
In addition to analyzing cumulative food intake, total measured brain 
dopamine, and total measured brain dopamine proportional to brain protein 
concentration for each of the two replicates, an ANOVA was performed to test for 
significance across replicate data.  The limited test group size of five rats for each 
dosage for both experiments may not be sufficient to yield significant results during 
analysis of the data.  Provided the comparison across replicates demonstrates 
consistency in results across both experiments, the comparison may yield significance 
given the larger combined test group size (n=10).  Each of the three aforementioned 
ANOVAs was conducted in SAS with combined data sets from both experiments. 
Hyperactivity 
Increased distance travelled and average velocity indicate increased levels of 
hyperactivity in the rat model.  Both distance travelled and average velocity were 
both obtained from the Noldus EthoVision software.  Averages of distance travelled 
and average velocity over the four days of testing were entered into SAS as the data 
set for the ANOVA performed.  Four groups (n=4) were assigned based on 
administered tartrazine dosage.  Means, standard errors, F-value, p-value, and R-
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squared value were returned from the ANOVA in addition to the results from a 








Body Weight and Food Intake 
The body weight and food intake was recorded for each rat during the 30 day 
period of tartrazine administration.  Figure 9 displays the results of the compiled body 
weight data for rats 1-20 and rats As-P over a duration of 30 days.  Figure 9a displays 
the average body weight for rats 1-20 and Figure 9b displays the average body weight 
for rats As-P.  For each group of 20 rats, body weights were divided into four 
experimental groups in order to assess average body weights across groups.  In Figure 
9a, rats 1-5 are in the control group, rats 6-10 are in the low dosage group, rats 11-15 
are in the medium dosage group, and rats 16-20 are in the high dosage group.  In 
Figure 9b, rats As, A, B, I, and J are in the control group, rats Bs, C, D, K, and L are 
in the low dosage group, rats Cs E, F, M, and N are in the medium dosage group, and 
rats Ds, G, H, O, and P are in the high dosage group.  To determine the effects of 
tartrazine on body weight, a one-way ANOVA followed by Duncan’s multiple range 
Test was used to test for statistical significance.  A probability level of less than 0.05 
percent was considered to be significant.  After these tests, no significant effects of 
tartrazine on body weight for rats 1-20 [F(3,4)=0.06, P=0.9813] and for rats As-P 
[F(3,4)=0.02, P=0.9957] were observed.  Duncan’s multiple range test also shows no 






 Cumulative food intake was also measured for rats 1-20 and As-P through the 
duration of 30 days of tartrazine administration.  The food intake was measured for 
each rat daily and then compiled for a total food intake value at the conclusion of 30 
days.  These results are shown in Figure 10. Figure 10a displays the average 
cumulative food intake for rats 1-20 and Figure 10b displays the average cumulative 
food intake for rats As-P.  Food intake is represented as an average for each 
experimental group.  Rats were divided into the experimental groups described above. 
In order to determine if tartrazine impacted the average cumulative food intake a one-
way ANOVA followed by Duncan’s multiple range test was used to test for statistical 
significance.  A probability level of less than 0.05 was considered to be significant. 
After the ANOVA analysis, no significant effects of tartrazine on cumulative food 
intake over the duration of the 30-day tartrazine administration period was observed 
for rats 1-20 [F(3,4)=1.65, P=0.2182] and for rats As-P [F(3,4)=1.54, P=0.2418]. 






Following administration of tartrazine, rats in Group Beta were subjected to a 
T-maze test to assess impulsivity.  This test yielded inconclusive results as rats As, 
Bs, Cs, and Ds were unable to successfully complete the training phase of the T-maze 
test. 
Rats in Groups Beta, Delta and Gamma were subjected to an open-field test to 
assess hyperactivity.  Hyperactivity is being quantified by the average distance 
traveled and average velocity during the open-field test where an increase in distance 
traveled and average velocity indicates an increase in hyperactivity.  The results from 
Group Beta were inconclusive as all rats jumped out of the open field box during 
trials.  The results of the successful trials for Groups Gamma and Delta are displayed 
in Figure 11.  Figure 11a displays the results of average distance traveled.  This value 
was calculated by averaging the distance each rat traveled during all four of its 15-
minute trials in the open-field.  Then, rats in Groups Delta and Gamma were clustered 
together by their experimental groups (Table 2)—control, low dosage, medium 
dosage, and high dosage—and the average distance traveled for each experimental 
group was calculated, and plotted versus the percent of tartrazine present in each 
group’s diet.  The data sets for Group Gamma and Delta were fitted with a linear 
trend.  As seen in Figure 11a, the linear trend for Group Gamma has equation 
y=2016.9x+3485.9 with an R2 value of 0.791.  The linear trend for Group Delta has 
equation y=1605.9x+3174.7 with an R2 value of 0.3835.  To determine the effects of 
tartrazine on average distance traveled a one-way ANOVA followed by Duncan’s 
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multiple range test was used for statistical significance.  A probability level of less 
than 0.05 was considered to be significant.  After a one-way ANOVA analysis, 
significant effects of tartrazine on total distance traveled in the open field test for rats 
in Groups Gamma and Delta [F(3,15)=6.97, P=0.0004] were observed.  Duncan’s 
multiple range test shows significance between test groups, as well, placing rats from 
the medium (0.15%) and high (0.45%) dosage groups in Group A, rats from the 
control and medium dosage groups in Group B, and rats from the low (0.05%) dosage 
group in Group C.  
Figure 11b displays the results of the average velocity of rat Groups Gamma 
and Delta during the open-field test.  This value was calculated by tracking the 
average velocity for each rat during all four of its 15-minute trials in the open-field. 
The rats in Groups Gamma and Delta were clustered together by their experimental 
group (Table 2) and the average velocity for each group was calculated and plotted 
versus the percent of tartrazine present in each group’s diet.  The data sets for Group 
Gamma and Delta were fitted with a linear trend in a similar fashion to the data sets 
displayed in Figure 11a.  As seen in Figure 11b, the linear trend for Group Gamma 
has equation y=2.5705x+3.8744 with an R2 value of 0.8873 and the linear trend for 
Group Delta has equation y=1.7616x+3.5472 with an R2 value of .3729.  To 
determine the effects of tartrazine on the average velocity a one-way ANOVA 
followed by Duncan’s multiple range test was used for statistical significance.  A 
probability level of less than 0.05 was considered to be significant.  After one-way 
ANOVA analysis, significant effects of tartrazine on average velocity in the open 
field test for Gamma/Delta rats [F(3,15)=6.83, P=0.0006] were observed.  Similarly 
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to the statistical results from total distance traveled, Duncan’s multiple range test 
shows significance between test groups as well, placing rats from the medium 
(0.15%) and high (0.45%) dosage groups in Group A, rats from the control and 









After the 30th day of tartrazine administration, rats in all groups were 
euthanized and their brain tissue was collected and assayed for brain dopamine.  The 
whole brains were frozen in isopentane and dry ice upon dissection.  The right-front 
and left-hind region of brains from rats 1-20 and As-P were assayed for brain 
dopamine with an ELISA assay.  Each brain region was also weighed and assayed for 
total brain protein with a BioRad assay.  The results of these assays are displayed in 
figures 12-15.  In order to assess the effects of tartrazine on brain dopamine across 
regions and experimental groups, the dopamine and whole protein results for brains 
1-20 and As-P were clustered by experimental dosage group (Table 2).  The 
dopamine concentration for each sample was normalized to the whole protein 
concentration (dopamine/protein) and those values were averaged in each 
experimental group as seen in Figures 12a, 13a, 14a, and 15a.  These normalized 
values were used to calculate the percent change in neural dopamine compared to the 
control group samples.  This data is represented in figures 12a, 13a, 14a, and 15a. 
In order to determine if tartrazine consumption had an effect of brain 
dopamine a one-way ANOVA followed by a Duncan’s multiple range test was used 
to test for statistical significance.  A probability level of less than 0.05 was considered 
to be significant.  After one-way ANOVA analysis, no significant effects of tartrazine 
on brain dopamine from the right front brain region for brains 1-20 [F(3,4)=0.33, 
P=0.8016] and for brains As-P [F(3,4)=2.96, P=0.0717] were observed.  Duncan’s 
multiple range test also shows no significance between test groups for brains 1-20. 
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However, it shows a difference between test groups for brains As-P, placing rats from 
low (0.05%), medium (0.15%), and high (0.45%) dosage groups in Group A and rats 
from control and low dosage groups in Group B.  After one-way ANOVA analysis, 
no significant effects of tartrazine on brain dopamine from the left hind brain region 
for brains 1-20 [F(3,4)=0.06, P=0.9821] and for brains As-P [F(3,4)=2.46, P=0.1028] 
were observed.  Duncan’s multiple range test also shows no significance between test 
groups for brains 1-20.  However, it shows a difference between test groups for brains 
As-P, placing rats from low (0.05%), medium (0.15%), and high (0.45%) dosage 
























Body Weight and Food Intake 
The original hypothesis of this study was that increasing the concentration of 
dietary tartrazine in the daily diet of the SHR model would result in a decrease in 
brain dopamine and increase in ADHD behavioral symptoms of impulsivity and 
hyperactivity.  During the 30 days of tartrazine administration, food consumption and 
body weight was recorded for each test subject.  This was done to assess if dietary 
tartrazine impacted either of these variables.  Statistical analysis of the average body 
weight and average cumulative food intake indicated that there is no statistically 
significant difference between experimental groups as determined by a one-way 
ANOVA and Duncan’s multiple range test.  This suggests that, provided all other 
experimental factors are controlled and consistent across test groups, any variation in 
measured brain dopamine and behavioral phenotypes can be attributed to the change 
in dietary tartrazine, and not changes in food intake or body weight.  Several factors 
that could have confounded these results include food that was spilled by the rat 
instead of orally ingested.  This variable was accounted for by daily measurements of 
each rat’s spillage on a collection platform placed beneath each cage; however, it is 
possible that residual food spillage could be unaccounted for in these measurements. 
The high p-value between experimental groups for average cumulative food intake 
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(p=0.2181 and p=0.2418) suggests that it is unlikely that marginal changes in 
cumulative food intake would result in statistical significance. 
Behavioral Analysis 
Following administration of tartrazine rats As-P were subjected to behavioral 
analyses.  Rats in the high dosage group showed significantly increased levels of 
hyperactivity in the open field maze when compared to the control group.  Generally, 
rats in the high dosage group travelled longer distances and exhibited an increase in 
average velocities.  The medium dosage group displayed no significant difference in 
distance travelled or averaged velocity from the control group.  The low dosage 
groups exhibited a statistically significant decrease in velocity and distance travelled 
when compared to the control group.  The results of the behavioral analysis shows 
that rats fed the highest concentration of tartrazine, (0.45%) exhibited higher 
hyperactive levels.  As a result, one can conclude that there is a relationship between 
amount of tartrazine consumed and hyperactivity levels.  There also seems to be a 
threshold in which tartrazine does affect hyperactivity, which explains why there was 
no significant difference in the medium group.  The most puzzling aspect of the 
results was that rats fed with the lowest dosage of tartrazine (0.05%) exhibited 
decreased levels of hyperactivity compared to the normal.  
The results from this experiment seem to be consistent with past findings in 
the field.  When rats were administered tartrazine in doses of 250 mg/kg and 500 
mg/kg the rats exhibited significantly increased levels of hyperactivity, quantified by 
the distance the rat traveled (Gao et. al., 2011).  Rats who were only given a 125 
mg/kg dose of tartrazine did not exhibit a significant difference (Gao et al., 2011).  
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Although the exact dosages of tartrazine in this experiment differed from 
those of Gao et al., researchers could only see significant changes in hyperactivity 
levels at higher dosages of tartrazine.  This does seem to support the idea that there is 
a threshold level in which tartrazine affects hyperactivity in an animal.  Other 
researchers have also examined the effect tartrazine has upon children’s 
hyperactivity.  When children with ADHD modified their diets to remove artificial 
food colors (AFCs), including tartrazine, there was a decrease in their hyperactivity 
(Arnold et al., 2012).  When these children resumed consumption of the AFCs they 
generally returned to their usual hyperactivity levels (Arnold et al., 2012). 
Furthermore, children who were given 6 doses of tartrazine reacted with an increase 
in irritability (Arnold et al., 2012).  By replicating what has been seen in humans, this 
experiment not only lends more validity of using SHR rat to model ADHD but also 
provides more evidence indicating a relationship between tartrazine and 
hyperactivity. 
Other research in the field has indicated that tartrazine may not have had an 
effect on hyperactivity.  Rats treated with a 4% concentration of a combination of 
artificial food dyes, including tartrazine, did not experience significant differences in 
mean distance traveled (Erickson et al., 2014).  Rats then underwent the open field 
test four times, each session lasting ten minutes (Erickson et al., 2014).  Yet, 
interactions between the different food dyes may have made it impossible to 
determine the true relationship between just tartrazine and hyperactivity.  Despite 
these conflicting results, the current experiment remains consistent with most of the 
information in the field.  
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Although the effect tartrazine has upon hyperactivity was not statistically 
significant in the lower dosages in this experiment, this does not rule out a 
relationship between the two.  One limitation of the behavioral analysis is the small 
sample size.  With a greater sample size, smaller and more nuanced differences in 
hyperactivity in the lower doses would be detected.  Another major factor that may 
have deterred the ability to properly examine the correlation between tartrazine 
consumption and hyperactivity of the SHR was faulty equipment.  While analyzing 
the videos using the Noldus EthoVision software, the tracking points would 
occasionally experience difficulties accurately tracking the rat.  This was due to a 
variety of reasons including an unfocused camera, poor camera quality, 
inconsistencies in the open field maze surface due to the glare of the lights in the 
room, which caused the software to lose track of the rat, and the edges of the box 
being cut out of some videos.  If the software had been able to track the rats’ 
movements consistently and without noise, the analysis would have taken 
approximately an hour.  However, the analysis took upwards of 13 hours, which 
confirmed that the software had difficulty tracking the rat.  
One confounding variable that may have affected our data is the order in 
which we performed the hyperactivity test on the rats.  Instead of randomly selecting 
the order of rats to be administered the task each day, we consistently ran every trial 
of hyperactivity experimentation with rats being tested in the same order.  At the 
onset of the experiment, rats in Groups Gamma and Delta were labeled A through P, 
and were thus tested in that order.  In short, all the rats in the control group were 
tested first, then all the rats in the low dosage group, then all the rats in the medium 
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dosage group, and finally all the rats in the high dosage group.  Since experimenters 
would be coming in and out of the rat housing room during this time and rats would 
be more agitated when they were brought back from the hyperactivity chamber, rats 
who were tested later may have sensed the increased disturbance in the room and 
became more agitated.  As a result, the increased stimulation and agitation of the rats 
tested later may have contributed to detecting higher hyperactivity levels than what 
was truly there.  As a result, the order in which we assessed the hyperactivity of the 
rats may have affected our data, resulting in higher than actual hyperactivity levels in 
the medium and high dosage groups. 
In the future, further research should be conducted to determine if even 
greater dosage of tartrazine – greater than 0.45% of the diet – affects hyperactivity. 
One could use this data to determine if increasing tartrazine will continue to cause an 
increase in hyperactivity or if there is a limit to the amount tartrazine can affect 
hyperactivity.  Using a finer range of doses around the high dosage may lead to the 
discovery of the exact threshold of tartrazine’s effects upon hyperactivity.  It is also 
important for future studies to determine whether a dosage above the NOEL of 
tartrazine would lead to significant measurable affects in hyperactivity. Conducting 
future studies on the effect of very low levels of tartrazine on hyperactivity may also 
lead to new insights regarding the relationship between the food dye and 
hyperactivity.  Since the results indicated significantly lower levels of hyperactivity 
when the rats were fed the smallest tartrazine dosages, it would be noteworthy to 
conduct more studies to understand why this phenomenon occurred.  By conducting 
the experiment with a wider tartrazine dosage range, we would be able to determine 
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whether there could be a dosage dependent curve, such as a sigmoidal curve.  Finally, 
it would be valuable to study the effects tartrazine has upon other symptoms of 
ADHD, including impulsivity.  By looking at a range of different characteristics, 
researchers would also gain a better understanding between the food additive and 
ADHD. 
It is also important to note that neural dopamine in SHR has been manipulated 
in the past using different chemicals relating to ADHD, including amphetamine and 
methylphenidate (Carboni et al., 2003). Although there were no consistent changes in 
neural dopamine in this experiment, the ability to even change dopamine levels in the 
SHR further validates the usage of SHR to model dopamine. Compared to other 
ADHD models, the WKY rat model in particular, the SHR has one of the most 
dynamic dopamine responses and most accurately mimics neural ADHD symptoms in 
humans. 
Biochemical Analysis 
As described previously, a decrease in neural dopamine levels has been 
implicated in human ADHD patients.  Increasing dopamine levels is a common target 
of pharmacotherapy.  Consequently, each rat test subject was assessed for brain 
dopamine levels following 30 days of tartrazine administration.  Brain tissue was 
harvested from each rat, sectioned into four regions, and assayed for brain dopamine 
and whole brain protein utilizing an ELISA and BioRad assay, respectively.  
Interestingly, in rat brains 1-20 there was a net decrease in brain dopamine 
between the control and high dosage groups in both the right-front and left-hind brain 
regions.  However in rat brains As-P, the opposite trend was observed with a net 
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increase in brain dopamine between the control and high dosage groups.  A one-way 
ANOVA and Duncan’s multiple range test were employed to determine if tartrazine 
had a statistically significant effect on brain dopamine.  The results of the ANOVA 
test indicated that there was no statistically significant change in brain dopamine in a 
dose-dependent manner in the right-front and left-hind regions of rat brains 1-20, and 
the right-front region of rat brains As-P.  The Duncan’s multiple range test also 
indicates that for rat brains 1-20 there is no statistically significant change in brain 
dopamine in the right-front region. 
 Despite the lack of statistically significant changes in the previously described 
regions, the Duncan’s multiple range test indicated that in the left-hind region of rat 
brains As-P there was as statistically significant difference in brain dopamine 
between the control and high dosage groups.  This indicates that dietary tartrazine 
could have had a measurable effect on brain dopamine in the highest dosage group. 
The Duncan’s multiple range test also indicated a statistically significant difference in 
brain dopamine between the medium and high dosage groups in the right-front region 
of brains As-P.  Both of these results suggest that in high doses, dietary tartrazine 
could have a measurable effect of brain dopamine in the SHR.  The discrepancy 
between the ANOVA and Duncan’s multiple range test suggests that there may be a 
threshold of dietary tartrazine needed to observe measureable effects in the rat model.  
As mentioned previously, in brains As-P there was net increase in brain 
dopamine between the control and high dosage groups.  This significantly contradicts 
the results of rat brains 1-20 as the expected hypothesis, and the literature (Volkow et 
al., 2009).  While these results could suggest a new hypothesis, there are several other 
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factors that may be able to explain this discrepancy.  Rats As-P were subjected to 
behavioral analysis prior to euthanasia, while rats 1-20 were not.  This could 
contribute to the difference in biochemical results.  Additionally, there were 
inconsistencies in the ELISA results for brains As-P, where some replicate samples 
were outside of the measurable range of the assay.  This could have been due to 
experimental error during the preparation of the samples or contamination in the kit. 
The ELISA kit used in this assay has a sensitivity limitation, which prevents it from 
detecting more subtle differences in brain dopamine concentration between samples.  
In future analysis, brain tissue could be individually sectioned with a cryostat and key 
regions of the brain described in the literature could be dissected and probed for 
dopamine with a Western Blot.  This experimental method would allow for more 
precise and sensitive detection of brain dopamine, which could resolve the 
discrepancies seen in these data sets.   
In the future, extensions of this research could include examining the kinetics 
of sulfanilic acid absorption as well as the rate of tartrazine absorption.  While this 
research studied the amount of tartrazine ingested, it is unclear how much of that 
tartrazine was actually metabolized by the test subjects.  To see how much of the 
tartrazine was absorbed or excreted, future studies could use biomarkers, such as 
radioactive sulfur or carbon, to visualize where the tartrazine or its metabolites 
traveled in the rat’s body.  
Lastly, previous literature has shown that dopamine regulation follows a 
circadian rhythm in humans and rats, and because rats are nocturnal, dopamine 
release is the highest at night.  Therefore, by switching the light and dark cycles in the 
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animal care room, we would have been able to dissect the SHR brains during the time 
of the highest possible dopamine release.  However, the animal care facility did not 
allow for control of the lights in the room, and the procedure room used to euthanize 
the SHR was unavailable at night.  In future projects, it would be best if the animal 
care facility being used permitted the switching of the light and dark cycles so that 
when euthanized, the SHR brains would be most active and releasing the amount of 
dopamine that would affect the brain, just as the dopamine in a human brain would be 








The results of the behavioral analysis indicate that dietary tartrazine increased 
hyperactivity in the SHR for certain dosage groups.  This is consistent with the 
original hypothesis of this study that predicted that increasing dietary tartrazine would 
result in an increase in hyperactivity.  The results of the impulsivity test were 
inconclusive due to incomplete analysis.  In order to test this portion of the 
hypothesis, the study could be completed with a more efficacious method of 
impulsivity testing, such as the operant condition chamber, which correlates reward-
uptake behavior with impulsivity.  The biochemical data suggests that dietary 
tartrazine does impact brain dopamine.  However, the data does not support the 
original hypothesis that there would be a net decrease in brain dopamine in response 
to dietary tartrazine.  Due to discrepancies in these data sets, though, further analysis 
is necessary to verify or nullify this hypothesis.  Additionally, there are other methods 
of statistical analysis that may be chosen for similar future studies.  For instance, the 
Duncan’s multiple range test may be used with the restriction of comparing 
experimental values to the standard zero value as opposed to simply comparing group 
means.  This could yield dose-dependent responses that may not otherwise be 
observed.  Ultimately, the results of this study do suggest that dietary tartrazine can 
impact ADHD-associated symptoms and behaviors.  
While this study was conducted in a rat model of ADHD, a similar experiment 
must be conducted in human patients to determine if the results of this study are 
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relevant in human ADHD.  ADHD is a behavioral disorder that negatively impacts 
that lives of patients, especially school-aged patients.  Understanding the role that 
dietary chemicals, such as tartrazine, have on the presentation of ADHD-like 
symptoms is important for improving the treatment options available for patients. 
Traditional pharmacotherapies have proven successful for managing ADHD in some 
patients, yet fail to work in other patient subset, and generally induce detrimental side 
effects regardless of the success of these drugs.  If patients can alleviate symptoms by 
employing less harmful measures, such as dietary modifications then efficacy of 
ADHD treatment may be improved.  Ultimately, additional research is necessary to 
verify the biochemical origin of ADHD and to identify key factors, dietary or 
otherwise, that may be able to mitigate the cause of ADHD and improve the quality 





Phenylalanine à Tyrosine à L-DOPA à Dopamine 
 
 
Figure 16: Synthesis of Tyrosine (The Medical Biochemistry Page, 1996) 
 
Phenylalanine is the essential amino acid, which is used to synthesize 
Tyrosine.  The metabolic pathway (Figure 16) for this synthesis involves the use of 
phenylalanine hydroxylase to add an alcohol (-OH) group in the para position and 
synthesize tyrosine (Elsworth & Roth, 1997).  Tyrosine is also ingested directly in the 
diet because it is a non-essential amino acid. The enzyme tyrosine hydroxylase is 
responsible for the conversion of tyrosine into L-3,4-dihydroxyphenylalanine (L-
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DOPA).  Along with O2, Fe2+, and tetrahydrobiopterin, tyrosine hydroxylase adds an 
alcohol group to the carbon adjacent to the already existent alcohol group.  In the 
final step of the pathway, DOPA decarboxylase, also known as aromatic amino acid 
decarboxylase (AADC decarboxylase; Elsworth et al., 1997), causes the carboxylic 
acid group (CO2-) to break its bond with the ethylamine group, forming dopamine as 










Date Transaction Debit/Credit Balance Items 
Sep-13 Yearly money from Gemstone +$600.0 $600.00  
Mar-14 Surgical West Pico Chemiluninescence Kit -$142.00 $458.00  
Mar-14 beta-actin Antibody -$279.00 $179.00  
Jul-14 Loss of Remaining Gemstone money -$179.00   
Aug-14 CFS3 Mini Grant +$2,500.00 $2,500.00  
Sep-14 Yearly money from Gemstone +$600.00 $3,100.00  
Oct-14 Home Depot -$49.92 $3,050.08 Wood and Paint 
Oct-14 Sigma Aldrich -$60.04 $2,990.04 Tartrazine 
Dec-14 FisherChem -$59.25 $2,930.79 Isopentane 
Jan-15 AGNR Dean matching +$1,250.00 $4,180.79  
Jan-15 Gemstone matching +$1,2500.00 $5,430.79  
Apr-15 CARF -$22.00 $5,408.79 Diet 
Apr-15 CARF -$22.00 $5,386.79 Diet 
Apr-15 CARF -$85.66 $5,301.13 Animal Care, Cage Changing, Rat 'P' Care 
Apr-15 CARF -$24.80 $5,276.33 Care for Rat 'P' 
Apr-15 CARF -$136.62 $5,139.71 Animal Care and Cage Changing - Dec. 
Apr-15 Chemstore -$15.48 $5,124.23 Dry Ice 
Apr-15 CARF -$1,467.56 $3,656.67 Group Alpha 
May-15 MyBioSource -$662.50 $2,994.17 Elisa Kit 
May-15 CARF -$24.00 $2,970.17 Care for Rat 'P' 
May-15 CARF -$94.86 $2,875.31 Animal Care 
Jul-15 Loss of Remaining Gemstone money -$600.00 $2,275.31  
Jul-15 Yearly money from Gemstone +$600.00 $2,875.31  
Jul-15 CARF -$319.35 $2,555.96 Group Beta 
Jul-15 CARF -$22.00 $2,533.96  
Jul-15 CARF -$24.48 $2,509.48 Animal Care - Jul. 
Aug-15 CARF -$91.80 $2,417.68 Animal Care 
Aug-15 CARF -$ 24.48 $2,393.20 Animal Care - Aug. 
Oct-15 MyBioSource -$662.50 $1,730.70 Elisa Kit 
Nov-15 Sara Kreshpanji -$37.30 $1,693.40 Tripod 
Nov-15 MyBioSource -$662.50 $1,030.90 Elisa Kit 
Oct-15 CARF -$91.80 $939.10 Animal Care - Oct. 
Oct-15 CARF -$22.00 $917.10 Diet 
Oct-15 CARF -$1,177.40 $(260.30) Groups Gamma and Delta Rats 
     
 Total spent $7,060.30   
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Appendix C  
 












































One Week of Habilitation 
One Day of Training 
Forced Trial to Large Reward 
Forced Trial to Small Reward 
Five Choice Trials 
Begin Training 
Did the rat choose the large 
reward four out of five times 
during the choice trials? 
Yes 
 
Did the rat choose the large 
reward four out of five times 



































Day 26 of Treatment 
Day 1 of Impulsivity Testing 
Large Reward Delayed 5 seconds 
Forced Trial to each reward arm 
Ten choice trials 
 
Day 27 of Treatment 
Day 2 of Impulsivity Testing 
Large Reward Delayed 10 seconds 
Forced Trial to each reward arm 
Ten choice trials 
 
Day 28 of Treatment 
Day 3 of Impulsivity Testing 
Large Reward Delayed 15 seconds 
Forced Trial to each reward arm 
Ten choice trials 
 
Day 29 of Treatment 
Day 4 of Impulsivity Testing 
Large Reward Delayed 20 seconds 
Forced Trial to each reward arm 




















































































Attention Deficit Hyperactivity Disorder: Type of brain disorder; symptoms 
include difficulty staying focused and paying attention, difficulty controlling 
behavior, and hyperactivity (over-activity). These symptoms can make it difficult for 
a child or adult with ADHD to succeed in school, get along with other children or 
adults, or finish tasks at home. 
Allura red AC: A red azo dye 
Artificial food coloring: A man-made, digestible substance used to give color to 
food 
Aspartame: A very sweet substance used as an artificial sweetener, chiefly in low-
calorie products 
Behavioral Assessment (in terms of ADHD): The measurement of behavior through 
direct observation and applications of the patient; interviews of parents and teachers 
Behavioral Inhibition: Refers to the consistent tendency of some children to 
demonstrate fear and withdrawal in novel situations 
Benzoate: A salt or ester of benzoic acid 
Carmoisine: Red 3, a synthetic red food dye from the azo dye group 
Catecholamine: Any of a class of aromatic amines that includes a number of 
neurotransmitters such as epinephrine and dopamine 
Cliff Avoidance Reaction (CAR): A natural tendency of animals to avoid a potential 
fall from a height 
Comorbid: Existing simultaneously with and usually independently of another 
medical condition  
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Dopamine Transporter Knockout Mouse (DAT-KO): A mouse model that is 
suggested to constitute an animal model of ADHD, produced by transgenic 
inactivation of the DAT gene 
Dopamine: A compound present in the body as a neurotransmitter and a precursor to 
other neurotransmitters 
Epinephrine: A hormone secreted by the adrenal medulla that is released into the 
bloodstream in response to physical or mental stress, as from fear or injury 
Erythrosine: Red 3, an organoiodine compound, specifically a derivative of fluorone, 
primarily used for food coloring 
Feingold Hypothesis: Hypothesis that states that hyperactivity in children may be 
caused by food additives such as artificial colors, artificial flavorings, and 
preservatives 
Food additive: A substance that becomes part of a food product when added during 
the processing or making of that food 
Functional magnetic resonance imaging (fMRI): A form of magnetic resonance 
imaging of the brain that registers blood flow to functioning areas of the brain  
Gene: A fundamental and functional unit of heredity that determines a characteristic. 
Also a sequence of nucleotides that is responsible for an organism’s phenotype 
Hyperactivity: A condition characterized by excessive restlessness and movement 
Impulsivity: Proceeding from natural feeling or impulse without external stimulus  
Maternal Phenylketonuria (MPKU): A mother with PKU passes on the disorder to 
her baby while he/she is still in the fetal developmental stage.  
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Methylphenidate: A prescription drug that is used to treat attention deficit 
hyperactivity disorder 
Monosodium glutamate: A compound that occurs naturally as a breakdown product 
of proteins and is used as a flavor enhancer in food (although itself tasteless) 
Naples High Excitability Rat: A rat model that features the main aspects of attention 
deficit hyperactivity disorder and display high activity levels in a Làt-maze 
Natural Salicylates: Salts, anions, or esters of salicylic acid 
Neurite growth: The growth of projections from the cell body of a neuron 
Neuro-imaging: Process of producing images of the structure of the structure or 
activity of the brain of the brain or other part of the nervous system by techniques 
such as magnetic resonance imaging or computerized tomography 
Neurodevelopmental: Impairments of the growth and development of the brain or 
central nervous system  
Neurotoxicity: Poisonous to nerves or nerve cells 
Neurotransmitter: A chemical substance that is released at the end of a nerve fiber 
by the arrival of a nerve impulse and, by diffusing across the synapse or junction, 
causes the transfer of the impulse to another nerve fiber, a muscle fiber, or some other 
structure 
Pharmacotherapy: Medical treatment by means of drugs. 
Pharmacostimulants: Drugs that provide biochemical or mental stimulus  
Phenylalanine: An essential amino acid that is a precursor to the non-essential amino 
acid tyrosine. L-phenylalanine is the most commonly ingested form by humans and is 
found in common food sources of protein. 
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Phenylketonuria (PKU): A rare genetic condition in which a baby is born without 
phenylalanine hydroxylase, the enzyme required to properly metabolize the amino 
acid phenylalanine. This defect leads to complications including abnormal tyrosine 
synthesis and dopamine deficiency.  
Polymorhphisms: Occurrence of something in several different forms 
Ponceau 4R: A synthetic colorant that may be used as a food coloring, from the azo 
family of dyes, red 
Positron emission tomography (PET): A technique for measuring brain function in 
living human subjects by detecting the location and concentration of tiny amounts of 
radioactive chemicals  
Prepulse Inhibition (PPI): A reduction in the startling and reflex reaction to a 
startle-eliciting stimulus shortly after a weaker stimulus (prepulse stimulus) 
Quinoline: An aromatic organic base, having a pungent tarlike odor, synthesized or 
obtained from coal tar, and used as a food preservative and in making antiseptics and 
dyes 
Serotonin: A compound present in blood platelets and serum that constricts the blood 
vessels and acts as a neurotransmitter 
“Stop and go” paradigm: A stop task is designed to measure response inhibition.  
The purpose is to measure the ability to inhibit a response when a go cue is 
unexpectedly accompanied by a stop clue. 
Strengths and Weaknesses of ADHD: Symptoms and Normal-behavior (SWAN) 
scale: An 18-item parent questionnaire for children 18 years and younger in order to 
assess symptoms of Attention-Deficit/Hyperactivity Disorder. 
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Sunset yellow: A synthetic yellow azo dye, manufactured from aromatic 
hydrocarbons from petroleum 
Tartrazine: A brilliant yellow synthetic dye derived from tartaric acid and used to 
color food, drugs, and cosmetics 
Tryptophan: an amino acid that is a constituent of most proteins 
Tyrosine: A non-essential amino acid that the human body synthesizes from the 
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